Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. - Wikidata - wikimedia - TriplyDB

Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer.

Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer.

http://www.wikidata.org/entity/Q40723187

about

Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Localized and Advanced Prostate Cancer: A Systematic Review and Meta-Analysis Prognostic value of inflammation in prostate cancer progression and response to therapeutic: a critical review Neutrophil-to-Lymphocyte Ratio Predicts PSA Response and Prognosis in Prostate Cancer: A Systematic Review and Meta-Analysis Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.Abiraterone for castration-resistant prostate cancer: adherence, survival and hospitalization : Analysis of a medical claims database.Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France.Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer.Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis.Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone.Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate.Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer.Novel agents for castration-resistant prostate cancer: Early experience and beyond.Prognostic nutritional index predicts initial response to treatment and prognosis in metastatic castration-resistant prostate cancer patients treated with abiraterone.Molecular characterization of a novel androgen receptor transgene responsive to MicroRNA mediated post-transcriptional control exerted via 3'-untranslated region.Prognostic factors of first-line docetaxel treatment in castration-resistant prostate cancer: roles of neutrophil-to-lymphocyte ratio in patients from Northwestern China.High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy.Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel.Validation of the neutrophil-to-lymphocyte ratio as a prognostic factor in a cohort of European prostate cancer patients.Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use.The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone.Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer.High preoperative neutrophil-lymphocyte ratio predicts biochemical recurrence in patients with localized prostate cancer after radical prostatectomy.Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer Neutrophils in cancer: prognostic role and therapeutic strategies.Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study.Neutrophil-lymphocyte ratio is prognostic but not predictive of response to Abiraterone in metastatic castration-resistant prostate cancer.Serum Pre-Albumin Predicts the Clinical Outcome in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Abiraterone.Platelet-lymphocyte and neutrophil-lymphocyte ratios are prognostic but not predictive of response to abiraterone acetate in metastatic castration-resistant prostate cancer.Current treatment strategies for advanced prostate cancer.Elevated preoperative neutrophil-lymphocyte ratio predicts upgrading at radical prostatectomy.Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio.Cancer-related inflammation: an emerging prognostic domain in metastatic castration-resistant prostate carcinoma.Diagnostic Gleason score and castration-resistant prostate cancer.Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel.Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer.

P2860

Q26751553-E43C64E8-0CA5-45E8-884D-6E3D942C9228 Q28073742-80B8F2BD-9696-4AD4-8310-A0F3BCABDEE8 Q28552296-74393275-0908-4110-8462-5BE636DAB765 Q30878925-DFED1853-DB0A-4AA7-9628-45F1F6413DF7 Q33841309-1F5F9B20-B526-4DE4-B65A-1B5844E70872 Q35358010-F4124C41-1FA0-47E6-9E31-C5558E90AB4D Q36081801-718AFCA7-8D60-44F5-B8DE-E960A1CD60E2 Q36167019-D4EF334D-263E-4F47-9BDB-3C067D9F2211 Q37335554-FDC6E386-14E4-49AA-94C7-ED5E4D50C8AA Q38388321-D2649EBE-DBC0-4D3B-84FA-203CF32F004F Q38438248-C11F196F-6604-446A-B0D7-442471C0CCFE Q38574684-A90D88BF-C96B-4351-B437-105F455817D0 Q38655670-85D29185-B588-40C9-B3D8-5F36EFC50AF9 Q38785291-42674CBD-D5D6-4D47-B31B-EF164FA92720 Q38978620-0DB31F29-40E4-4B84-9A6A-E6EA3F893630 Q38994309-8A0D4B8F-759D-4F14-A913-6B9DDBC2C89F Q39031750-9CEDA1E9-1881-412D-8E6D-A3EAC03B39C4 Q39050892-BB04433D-5915-4642-81B3-BF634C866CEA Q39189394-315D7484-3DB8-4808-AF24-D46643438A35 Q40332155-6752E1D3-070B-499B-9972-027AE4CB8C71 Q40830449-463261BA-5A8E-4085-B874-60D1973E3C1C Q40960782-F6BB99E3-E28F-4B2A-BF67-9E61009A5375 Q41191641-C917654C-531A-43C5-B478-F72FB9CE42FC Q41431390-E7C7BF73-0CAD-458E-A714-ADEA9BA4B653 Q41867950-E4BDA9E2-F2F9-4BC6-9B1E-DB4D7A32ED68 Q43144351-53881FA6-B9C7-4704-A951-5D82C24027F8 Q47449416-B2D991F8-39EA-4BBD-9F3A-24B5B388F3C5 Q48110694-6E3318F6-351D-4FDB-B4AF-EA2C4D3FF540 Q48561494-3E0B9B06-8729-42E9-90E8-8A638671A056 Q49919238-646A7DE4-410C-4388-A8D3-1B57C3CE3076 Q53036812-6E4EC345-46A0-45C5-BA7D-287916D908F9 Q53036820-A51D63B7-33AD-4A59-8A99-46DB8B54A4AA Q53789514-70335209-25C9-49DD-BF1C-F412B76ED677 Q53822455-217762A7-AF4A-4B50-BBEB-D6E10E0C59B0 Q55441916-BB777616-F93F-4BD6-8BB1-8D78CEDC9847

P2860

Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer.

http://www.wikidata.org/entity/Q40723187

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Clinical variables associated ...... ion-resistant prostate cancer.

@en

type

label

Clinical variables associated ...... ion-resistant prostate cancer.

@en

prefLabel

Clinical variables associated ...... ion-resistant prostate cancer.

@en

P1433

Q40723187-037A1DE5-2532-4BA3-BC8F-7AE39E1E60FE

P1476

Q40723187-FA3E7B04-1191-4172-ADC6-E1B16C810279

P2093

Q40723187-02562C2B-CA8C-4213-A4A7-1DA1D0B1E9BB

Q40723187-2B311FD7-F2B9-4BA8-8BBB-42F05F079415

Q40723187-4399AA3B-B945-46E6-9A33-07324E1F051F

Q40723187-56480554-81D7-41B8-B149-8FB8105575D7

Q40723187-5B96C51F-EC7A-4DE1-9A7F-945B080C1B67

Q40723187-810C12BD-E9CF-4077-B625-58DEA317E015

Q40723187-97B54DA9-E0FD-4410-A5C2-F1F48C6784C3

Q40723187-AA10F414-A218-469C-90C6-9C295BA5D271

Q40723187-C945505A-EB8B-4FFC-BAA9-DC036DA4340E

Q40723187-E74C1181-67DF-4A2B-9809-E0092A1EF676

P2860

Q40723187-147C3A74-00CD-4BF5-9BA2-4D77BC11302E

Q40723187-26E7C5F6-61C6-4432-BD1E-B3F19AB3BE84

Q40723187-34CA7D10-B50B-4C97-B166-B1C68D9F9B82

Q40723187-5958D6BC-4C43-4840-B672-0D23CA6C5E73

Q40723187-6189103B-EB56-4980-B2E9-1F260FE95C64

Q40723187-70568D9B-3D77-4B5B-BFB9-EB175C53DB64

Q40723187-74893838-3725-4392-A288-619F6C4AD568

Q40723187-7C173A51-8311-4D5B-A9BE-E7C38D5943A8

Q40723187-7E14F312-822A-472A-A035-DEC80D26D3A4

Q40723187-852A2BCD-7F0B-4460-8DE0-C31CE2B9CA63

P304

Q40723187-50C56FFC-8B05-4BBE-99B4-E5E818E7AB8F

P31

Q40723187-AFD8BB8D-11EE-428B-A612-DC181A603EAD

P356

Q40723187-9C3ECF0F-FFAA-4C4E-8F05-EE09374F9B5A

P433

Q40723187-4460BBD7-628B-42F3-BCD5-80720C83A860

P478

Q40723187-958DEFB5-708F-42C9-A57D-FD1917B584B1

P50

Q40723187-73AEEC26-46C4-413C-B9DC-1608F6F7F1CD

Q40723187-C9E6031B-D44A-4D5A-A47F-E67D941F7867

Q40723187-F477C315-A2A3-42F4-91EF-501248381C47

P577

Q40723187-4B31C93C-3531-4875-B3D3-C9C208D6A311

P698

Q40723187-0FEB0F61-2737-466E-8B9C-CF8384687C84

P932

Q40723187-82DDB4C1-926F-4EFD-B9E6-65D499C024E9

P356

P1433

Annals of Oncology

P1476

Clinical variables associated ...... tion-resistant prostate cancer

@en

P2093

A J Templeton

http://www.w3.org/2001/XMLSchema#string

A Omlin

http://www.w3.org/2001/XMLSchema#string

C Pezaro

http://www.w3.org/2001/XMLSchema#string

D Keizman

http://www.w3.org/2001/XMLSchema#string

F Vera-Badillo

http://www.w3.org/2001/XMLSchema#string

I F Tannock

http://www.w3.org/2001/XMLSchema#string

J J Knox

http://www.w3.org/2001/XMLSchema#string

J S de Bono

http://www.w3.org/2001/XMLSchema#string

J-A Seah

http://www.w3.org/2001/XMLSchema#string

R Leibowitz-Amit

http://www.w3.org/2001/XMLSchema#string

P2860

Hallmarks of Cancer: The Next Generation

Abiraterone in metastatic prostate cancer without previous chemotherapy

Inflammation and cancer: back to Virchow?

Alpha emitter radium-223 and survival in metastatic prostate cancer

Increased survival with enzalutamide in prostate cancer after chemotherapy

Abiraterone and increased survival in metastatic prostate cancer

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram.

P304

657-662

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDT581

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Gerhardt Attard

Eshetu G. Atenafu

Anthony M Joshua

P577

2014-01-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24458472

http://www.w3.org/2001/XMLSchema#string

P932

4433513

http://www.w3.org/2001/XMLSchema#string